Cardiac Transplantation
15
0
1
9
Key Insights
Highlights
Success Rate
69% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
26.7%
4 terminated out of 15 trials
69.2%
-17.3% vs benchmark
40%
6 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs
Oral Water Ingestion in Heart Transplant Patients
Anatomical and Functional Assessment of Ex-vivo Coronary Perfusion
Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation
Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study
Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients
Osteoporosis Prevention After Heart Transplant
Everolimus in de Novo Heart Transplant Recipients
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept
Absolute Myocardial Perfusion Measurement in the Transplanted Heart